Li Y, Schofield E, Hay J
Quant Method Psychol. 2024; 19(3):265-280.
PMID: 39323564
PMC: 11423781.
DOI: 10.20982/tqmp.19.3.p265.
Tonder J, Bonnelykke-Behrndtz M, Laurberg T, Rossell E, Sollie M
BMC Cancer. 2024; 24(1):812.
PMID: 38972968
PMC: 11229239.
DOI: 10.1186/s12885-024-12598-8.
Al-Adwan S, Alqaisi K, Al Katheri G
Clin Cosmet Investig Dermatol. 2024; 17:17-29.
PMID: 38193026
PMC: 10773247.
DOI: 10.2147/CCID.S433447.
Liu J, Hu X, Xin W, Wang X
Curr Med Chem. 2023; 31(37):6084-6109.
PMID: 37877505
DOI: 10.2174/0109298673267553231017053329.
Talwar J, Laub D, Pagadala M, Castro A, Lewis M, Luebeck G
Am J Hum Genet. 2023; 110(7):1138-1161.
PMID: 37339630
PMC: 10357503.
DOI: 10.1016/j.ajhg.2023.05.013.
Melanoma risk prediction based on a polygenic risk score and clinical risk factors.
Wong C, Dite G, Spaeth E, Murphy N, Allman R
Melanoma Res. 2023; 33(4):293-299.
PMID: 37096571
PMC: 10309112.
DOI: 10.1097/CMR.0000000000000896.
Cutaneous Melanoma versus Vulvovaginal Melanoma-Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy.
Lorenz A, Kozlowski M, Lenkiewicz S, Kwiatkowski S, Cymbaluk-Ploska A
Cancers (Basel). 2022; 14(20).
PMID: 36291906
PMC: 9600893.
DOI: 10.3390/cancers14205123.
Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster Trial.
Marce D, Vilain-Abraham F, Bridou M, Quereux G, Dupuy A, Lesimple T
Cancers (Basel). 2022; 14(16).
PMID: 36010858
PMC: 9406196.
DOI: 10.3390/cancers14163864.
Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of Pathogenic Variants.
Pauley K, Khan A, Kohlmann W, Jeter J
Front Oncol. 2022; 12:837057.
PMID: 35372037
PMC: 8967159.
DOI: 10.3389/fonc.2022.837057.
Risk factors for the development of Spitz neoplasms.
Benton S, Roth A, Khan A, Zhao J, Kim D, Compres E
Pediatr Dermatol. 2022; 39(2):220-225.
PMID: 35187702
PMC: 9306590.
DOI: 10.1111/pde.14957.
The Future of Precision Prevention for Advanced Melanoma.
Lee K, Betz-Stablein B, Stark M, Janda M, McInerney-Leo A, Caffery L
Front Med (Lausanne). 2022; 8:818096.
PMID: 35111789
PMC: 8801740.
DOI: 10.3389/fmed.2021.818096.
Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide -Methyltransferase as a Biomarker in Skin Cancers.
Campagna R, Pozzi V, Sartini D, Salvolini E, Brisigotti V, Molinelli E
Cancers (Basel). 2021; 13(19).
PMID: 34638427
PMC: 8508019.
DOI: 10.3390/cancers13194943.
Effect of hypoxia factors gene silencing on ROS production and metabolic status of A375 malignant melanoma cells.
Spakova I, Rabajdova M, Mickova H, Graier W, Marekova M
Sci Rep. 2021; 11(1):10325.
PMID: 33990669
PMC: 8121821.
DOI: 10.1038/s41598-021-89792-2.
Genotypic vs Phenotypic Risk Assessment for Melanoma.
Sargen M, Tucker M
J Natl Cancer Inst. 2021; 113(10):1279-1280.
PMID: 33837776
PMC: 11186435.
DOI: 10.1093/jnci/djab077.
The association between citrus consumption and melanoma risk in the UK Biobank.
Marley A, Li M, Champion V, Song Y, Han J, Li X
Br J Dermatol. 2021; 185(2):353-362.
PMID: 33782946
PMC: 8373643.
DOI: 10.1111/bjd.19896.
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities.
Eddy K, Shah R, Chen S
Front Oncol. 2021; 10:626129.
PMID: 33614507
PMC: 7891057.
DOI: 10.3389/fonc.2020.626129.
Overcoming Immune Evasion in Melanoma.
Eddy K, Chen S
Int J Mol Sci. 2020; 21(23).
PMID: 33256089
PMC: 7730443.
DOI: 10.3390/ijms21238984.
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility.
Landi M, Bishop D, Macgregor S, Machiela M, Stratigos A, Ghiorzo P
Nat Genet. 2020; 52(5):494-504.
PMID: 32341527
PMC: 7255059.
DOI: 10.1038/s41588-020-0611-8.
Patterns and sources of information about family melanoma risk among melanoma survivors.
Zapolska J, Hay J, Li Y, Orlow I, Begg C, Berwick M
Melanoma Manag. 2018; 3(2):105-111.
PMID: 30190879
PMC: 6094696.
DOI: 10.2217/mmt-2015-0003.
Barriers to risk-understanding and risk-reduction behaviors among individuals with a family history of melanoma.
FitzPatrick L, Hay J
Melanoma Manag. 2018; 1(2):185-191.
PMID: 30190823
PMC: 6094692.
DOI: 10.2217/mmt.14.24.